P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL

• T. wang,
• X. sun,
• L. qiu,
• H. su,
• J. cao,
• Z. li,
• Y. song,
• L. zhang,
• S. yi,
• L. qiu,
• J. zhou,
• H. wu,
• W. zhang,
• J. li,
• K. zhou,
• H. zhou,
• Y. yang,
• Z. li,
• H. cen,
• Z. cai,
• Z. zhang,
• W. fu,
• J. jin,
• F. li,
• W. wu,
• X. gu,
• W. zhu,
• L. liu,
• Z. li

Affiliations

T. wang

1 Department of Lymphoma and Myeloma, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

X. sun

2 department of medical oncology, the second hospital of dalian medical university, dalian

L. qiu

3 Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin

H. su

4 Department of Lymphoma, The Fifth Medical Center of PLA General Hospital, Beijing

J. cao

5 Fudan University Shanghai Cancer Center, Shanghai

Z. li

6 Sun Yat-sen University Cancer Center, guangzhou

Y. song

7 Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing

L. zhang

8 West China Hospital, Sichuan University, chengdu

S. yi

9 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

L. qiu

9 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

J. zhou

10 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

H. wu

11 Department of Medical Oncology, Hubei Cancer Hospital, Wuhan

W. zhang

12 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing

J. li

13 Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

K. zhou

14 Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou

H. zhou

15 Department of Lymphoma & Hematology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha

Y. yang

16 Department of Lymphoma and Head and Neck Cancer, Fujian Provincial Cancer Hospital, The Affiliated Tumor Hospital of Fujian Medical University, Fuzhou

Z. li

17 Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen

H. cen

18 Department of Haematology/Oncology and Paediatric Oncology, Guangxi Medical University Affiliated Cancer Hospital, Nanning, China, Nanning

Z. cai

19 Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

Z. zhang

20 Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Chengdu

W. fu

21 Department of Hematology, The Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai

J. jin

19 Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

F. li

22 Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang

W. wu

23 Department of Internal Medicine and Oncology, Zhongshan Hospital, Xiamen University, Xiamen

X. gu

24 Department of Hematology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine

W. zhu

25 Department of Oncology, Zhujiang Hospital of Southern Medical University, Guangzhou

L. liu

26 Department of Hematology, The Fourth Hospital of Hebei Medical Universit, Shijiazhuang

Z. li

27 Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China